News | April 09, 2014

New Ultrasound Method Predicts Blood Clots in the Heart, Brain

Cardiac Ultrasound Blood Clots Heart Brain ACC.14

April 9, 2014 — A study with a new ultrasonic scanning technique shows that scanning of the carotid arteries can reveal who is at high risk of being hit by a blood clot. Scanning examines the patient for atherosclerosis, which causes the vast majority of blood clots in the heart, brain or elsewhere in the body

The study "Detection and Impact of Subclinical Coronary and Carotid Atherosclerosis on Cardiovascular Risk Prediction and Reclassification in Asymptomatic U.S. Adults: Insights from the High Risk Plaque Bioimage Study," was presented at the American College of Cardiology (ACC) 2014. Nearly 6,000 apparently healthy Americans participated in the study from 2009 to 2010. The patients received an ultrasound scan of the carotid arteries and computed tomography (CT) scans of the heart. They were then followed to ascertain who got blood clots and other cardiovascular diseases.

Henrik Sillesen, M.D., department of vascular surgery, University Hospital Copenhagen, Denmark, was responsible for conducting and analyzing all cardiac ultrasound scans. He said, "By scanning both carotid arteries and calculating a measure of how much atherosclerosis was present, we could show that those who had much atherosclerosis were three times as likely to develop coronary heart disease in the form of thrombosis, need for heart surgery, etc., as those who had veins without evidence of atherosclerosis. Even those with only moderate amounts of atherosclerosis had more than twice as likely as those with normal veins. "

Ultrasound proved to be just as good as cardiac CT scan, which hitherto has been considered the best method. Since ultrasound equipment is smaller, less expensive, mobile and does not use X-rays, the study suggests this method may be better than CT for the study of healthy people who want to know if they are at risk.

For more information: content.onlinejacc.org/article.aspx?articleid=1856105

 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now